PXD073706

PXD073706 is an original dataset announced via ProteomeXchange.

Title	The Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections
Description	The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that the combination of remdesivir and ivermectin is highly potent and synergistic in inhibiting the replication of murine hepatitis virus, a surrogate model for SARS-CoV-2. Time-of-addition and time-of-removal assays were performed to determine the viral replication processes affected. The interactions between the drug combination, virus and host were investigated by proteomics and bulk RNA sequencing of MHV-infected H2.35 mouse liver epithelial cells. The combination (at their respective IC50 concentrations) drastically diminished the coronavirus titer by ~4log10 greater than the respective monotherapies. Based on proteomic and transcriptomic analyses, viral protein and RNA levels were significantly depressed upon combination treatment. While remdesivir exhibited considerable negative effects upon host RNA processes, ivermectin resulted in the upregulation of host protein processes (e.g. response to unfolded protein; protein insertion into ER membrane). Molecular pathways affected by the combination treatment were markedly distinct from the monotherapies, and indicated that ivermectin enhances remdesivir by modulating critical host processes to synergistically exert its inhibitory effect on the coronavirus replication cycle.
HostingRepository	PRIDE
AnnounceDate	2026-09-07
AnnouncementXML	Submission_2026-09-07_04:20:18.523.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Ryan Lew
SpeciesList	scientific name: Mus musculus (Mouse); NCBI TaxID: NEWT:10090;
ModificationList	No PTMs are included in the dataset
Instrument	TripleTOF 6600

Revision	Datetime	Status	ChangeLog Entry
0	2026-01-28 03:07:14	ID requested
⏵ 1	2026-09-07 04:20:19	announced

10.3390/cells15131146;

Lew RZZ, Tay DJW, Ong JWX, Low JH, Liu J, Wang Y, Chu JJH, Andiappan AK, Tan KS, Chow VTK, Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections. Cells, 15(13):(2026) [pubmed]

submitter keyword: Remdesivir

Ivermectin

combination therapy

repurposed drugs

murine hepatitis virus

proteomics

transcriptomics

Vincent Tak Kwong Chow
contact affiliation	Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
contact email	micctk@nus.edu.sg
lab head
Ryan Lew
contact affiliation	National University of Singapore, Department of Microbiology and Immunology
contact email	e0053617@u.nus.edu
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD073706

PRIDE project URI

• PRIDE
  1. PXD073706
     1. Label: PRIDE project
     2. Name: The Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections